4DMedical (ASX:4DX) Could Be 24% Undervalued On Azra AI Partnership
4DMedical (ASX:4DX) is in focus after Azra AI announced an OEM and reseller partnership that links 4DMedical’s lung imaging software with Azra’s real-time patient identification platform across multiple pulmonary care pathways.
See our latest analysis for 4DMedical.
The Azra AI partnership comes as 4DMedical trades at A$3.79, with a 30-day share price return of 10.5% and a 90-day share price return of 15.55%, while the 1-year total shareholder return is very large and points to strong momentum despite a year-to-date share price decline of 16.52% and a softer 7-day share price return of 8.01%.
If this kind of healthcare AI linkup has your attention, it could be worth scanning for other listed companies pushing AI into clinical workflows through the 7 healthcare AI stocks.
4DMedical now has a high profile AI partner and strong recent share price momentum. The harder question is whether the current A$3.79 price, along with the very large 1 year return, still leaves enough value on the table.
Most Popular Narrative: 24% Undervalued
4DMedical’s most followed valuation narrative pegs fair value at A$4.97 per share, compared with the current A$3.79 price, which sets up a wide expectations gap.
The expansion into underutilized regions such as North and South Australia and potentially Canada, coupled with the new hire of Philips' sales force presence, could lead to increased site penetration and scan volume, directly impacting revenue and future earnings positively.
The development and expected FDA approval of the CT:VQ technology, which offers logistical improvements over current nuclear medicine solutions, present a significant opportunity to capture a share of the $1 billion market, potentially enhancing net margins through the provision of superior cost saving technology.
Want to see what is behind that A$4.97 fair value for 4DMedical? The narrative leans on rapid top line compounding, margin repair, and a rich future earnings multiple.
Result: Fair Value of A$4.97 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, 4DMedical still faces key hurdles, including cash burn that exceeds its A$5.8 million in annual revenue and short term funding needs that may require further capital raises.
Find out about the key risks to this 4DMedical narrative.
Next Steps
With investors split between the upside potential and the funding and execution risks around 4DMedical, it makes sense to move quickly and test the numbers for yourself. Start by weighing both sides of the story, then dig into the 1 key reward and 5 important warning signs.
Looking for more investment ideas beyond 4DMedical?
If you like the setup around 4DMedical, do not stop here. The next smart move is broadening your watchlist with fresh, high conviction ideas.
- Target potential value upside by reviewing companies that screen well on quality and pricing through the 14 high quality undervalued stocks.
- Prioritise resilience by checking stocks that combine lower risk profiles with steadier fundamentals using the 10 resilient stocks with low risk scores.
- Get ahead of the crowd by scanning a screener containing 11 high quality undiscovered gems before the wider market pays attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com